I have a really positive sense that Kevetrin will become an important drug with significant commercial applications. It also looks like anything commercialized is many years away. In that time, other companies will be working on their own magic bullets. How will all the puzzle pieces fit years from now?
The results seem to be statistically significant. With increased study, target cancer therapies should be enhanced very meaningfully.
There are lots of unknowns.
Study of Kevetrin will likely seek to determine which cancers respond best, what dosages are optimum, how best to administer, combined therapies or stand alone, chemotherapy and/or preventative, stages of cancer, and which patient groups will benefit most.
When there are more answers than questions, Kevetrin will be a blockbuster (IMO).
Possibilities seem very encouraging. Very positive. Kevetrin is an important drug candidate.
Now, management needs to get the word out in a way that will support the company and Kevetrin development. Ultimately, this will reflect in the share price.
The company has not gotten through to wall street or main street. I think Leo knows this. I think that is one reason why Leo is writing PR's. Often, it seems.
Maybe, Leo needs to reconsider how he is writing the PR's. He is not connecting with his target audiences in the right way. Maybe he should get some help.
There is phenomenal news. There is the message. Message is being received. Market reaction is not very enthusiastic.
So, message being sent is not being received in the manner expected.
Messenger should reconsider the message to get the desired reaction.
News 
Market Data 
Discover 
